Enterprise Value
547.4M
Cash
823M
Avg Qtr Burn
-22.45M
Short % of Float
10.49%
Insider Ownership
28.85%
Institutional Own.
27.32%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Izokibep Details Axial spondyloarthritis | Phase 3 Initiation | |
Izokibep Details Psoriatic arthritis | Phase 2/3 Data readout | |
Izokibep Details Uveitis | Phase 2/3 Update | |
Izokibep Details Hidradenitis suppurativa | Phase 2/3 Update | |
SLRN-517 Details Allergy, Inflammatory disease, KIT/Mast cell diseases | Phase 1/2 Data readout | |
Lonigutamab Details Thyroid Eye Disease | Phase 1/2 Data readout |